Segment Information Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022		Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue		$ 55,430	$ 66,398	[1]	$ 216,700	$ 379,421	[1]
Segment research and development expense:
Total segment research and development expense		156,662	261,460	[1]	463,583	875,095	[1]
Segment general and administrative expense:
General and administrative		82,028	435,221	[1]	295,802	1,308,416	[1]
Segment operating income (loss):
Total segment operating loss		(286,393)	(654,938)	[1],[2]	(686,289)	(1,978,088)	[1],[2]
Operating expenses not allocated to segments:
Stock-based compensation					187,047	1,822,472	[3]
Depreciation and amortization					57,670	26,885	[3]
Employer payroll taxes		1,100	200		4,300	7,200
Corporate, Non-Segment
Operating expenses not allocated to segments:
Stock-based compensation	[4]	53,647	563,385	[2]	191,324	1,829,690	[2]
Depreciation and amortization		21,060	8,917	[2]	57,670	26,885	[2]
Asset impairment		112,403	0	[2]	121,404	0	[2]
Change in fair value of contingent consideration liability		1,764	(242)	[2]	10,217	58	[2]
Cell Engineering and Biosecurity
Revenue:
Total revenue		55,430	66,398	[2]	216,700	379,421	[2]
Segment research and development expense:
Total segment research and development expense		91,202	65,976	[2]	276,902	179,295	[2]
Segment general and administrative expense:
General and administrative		54,824	58,645	[2]	198,078	147,583	[2]
Segment operating income (loss):
Total segment operating loss		(97,519)	(82,878)	[2]	(305,674)	(121,455)	[2]
Cell Engineering | Operating Segments
Revenue:
Total revenue		37,176	24,679	[2]	116,555	90,409	[2]
Segment research and development expense:
Total segment research and development expense		90,889	65,589	[2]	275,494	177,948	[2]
Segment general and administrative expense:
General and administrative		42,617	41,606	[2]	155,216	104,900	[2]
Segment operating income (loss):
Total segment operating loss		(96,330)	(82,516)	[2]	(314,155)	(192,439)	[2]
Biosecurity | Operating Segments
Revenue:
Total revenue		18,254	41,719	[2]	100,145	289,012	[2]
Segment cost of revenue:
Total segment cost of revenue		6,923	24,655	[2]	47,394	173,998	[2]
Segment research and development expense:
Total segment research and development expense		313	387	[2]	1,408	1,347	[2]
Segment general and administrative expense:
General and administrative		12,207	17,039	[2]	42,862	42,683	[2]
Segment operating income (loss):
Total segment operating loss		$ (1,189)	$ (362)	[2]	$ 8,481	$ 70,984	[2]

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

[2] As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

[3] As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.

[4] Includes $1.1 million and $0.2 million in employer payroll taxes for the three months ended September 30, 2023 and 2022, respectively, and $4.3 million and $7.2 million in employer payroll taxes for the nine months ended September 30, 2023 and 2022, respectively.